[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@drughunter_com](/creator/twitter/drughunter_com)
"BMS Rescues Oral Macrocyclic Peptide PD-L1 Inhibitor Program Through a HSA Binding Tail BMS-986238 is a second-generation macrocyclic peptide inhibitor of PD-L1 signaling that originated from a long-term collaboration between BMS and PeptiDream. It stems from a first-generation inhibitor which failed in the clinic due to poor PK by including a serum albumin binding motif that extends the half-life. Recently disclosed at the ACS Spring 2025 meeting we reveal how this macrocycle was initially discovered and the subsequent HSA binding and formulation optimization of this remarkable compound."  
[X Link](https://x.com/drughunter_com/status/1917598969556873417) [@drughunter_com](/creator/x/drughunter_com) 2025-04-30T15:16Z 10.7K followers, 28.2K engagements


"More than XX% of human proteins are still considered undruggable because they lack known or well-defined binding pockets that can be effectively targeted by small molecules. In this Flash Talk Daniel Nomura Professor of Chemical Biology and Molecular Therapeutics will present his groups recent efforts applying chemoproteomic approaches to identify and pharmacologically target novel ligandable hotspots within disease-relevant proteins. Daniel will also highlight how chemoproteomic platforms have expanded the scope of emerging therapeutic modalities including targeted protein degradation and"  
[X Link](https://x.com/drughunter_com/status/1977834988121780304) [@drughunter_com](/creator/x/drughunter_com) 2025-10-13T20:33Z 10.7K followers, 1544 engagements


"ETN029 is a DLL3-targeted macrocyclic peptide with a DOTA chelator enabling theranostics: 111In for imaging and 225Ac for therapy. Single-dose 225Ac-ETN029 drove tumor regression in DLL3-positive CDX models. Ph. X planned for late 2025. Read more:"  
[X Link](https://x.com/drughunter_com/status/1976026567319884179) [@drughunter_com](/creator/x/drughunter_com) 2025-10-08T20:47Z 10.7K followers, 2551 engagements


"Dordaviprone received FDA accelerated approval for the treatment of DMG (diffuse midline glioma) harboring the H3(K27M) mutation in patients X year old with progressive disease after prior therapy. It is the first FDA-approved systemic therapy specifically for H3(K27M)mutant DMGa disease that primarily affects children and young adultsand the first imipridone from the @Chimerix/@JazzPharma partnership to reach approval. Read more:"  
[X Link](https://x.com/drughunter_com/status/1977028459051270241) [@drughunter_com](/creator/x/drughunter_com) 2025-10-11T15:08Z 10.7K followers, 3445 engagements


"The second of a two-part review on CDK4/6 inhibitors focuses on the approved molecules that transformed the treatment of HR+/HER2- breast cancer. Palbociclib (Pfizer) ribociclib (Novartis) and abemaciclib (Eli Lilly) have shown a significant extension in progression-free survival when combined with endocrine therapy. Though all three share a common ATP-competitive binding motif their divergent chemotypes lead to differences in selectivity and tolerability. - palbociclib was the first CDK4/6 inhibitor approved and was optimized for CDK4/6 selectivity - ribociclib achieved 10000 fold"  
[X Link](https://x.com/drughunter_com/status/1978565063884595697) [@drughunter_com](/creator/x/drughunter_com) 2025-10-15T20:54Z 10.7K followers, 1209 engagements